Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Is there a genetic factor in flecainide toxicity?

Literature DB >> 3144374

Is there a genetic factor in flecainide toxicity?

J Beckmann¹, R Hertrampf, U Gundert-Remy, G Mikus, A S Gross, M Eichelbaum.

Abstract

Entities: Chemical Disease

Mesh：

Substances：
Sparteine
Flecainide

Year: 1988 PMID： 3144374 PMCID： PMC1834956 DOI： 10.1136/bmj.297.6659.1316

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

3 in total

1. Polymorphic drug oxidation in humans.

Authors: M Eichelbaum
Journal: Fed Proc Date: 1984-05-15

2. Oral flecainide acetate for the treatment of ventricular arrhythmias.

Authors: J L Anderson; J R Stewart; B A Perry; D D Van Hamersveld; T A Johnson; G J Conard; S F Chang; D C Kvam; B Pitt
Journal: N Engl J Med Date: 1981-08-27 Impact factor: 91.245

3. Pharmacodynamics and side effects of flecainide acetate.

Authors: D M Salerno; G Granrud; P Sharkey; J Krejci; T Larson; D Erlien; D Berry; M Hodges
Journal: Clin Pharmacol Ther Date: 1986-07 Impact factor: 6.875

3 in total

13 in total

1. Acquired long QT syndrome and ventricular tachycardia in a patient on flecainide therapy.

Authors: Chang-Woo Son; Sang-Hee Lee; Dong-Gu Shin; Gue-Ru Hong; Jong-Seon Park
Journal: J Cardiol Cases Date: 2011-03-29

Review 2. Adverse effects of class I antiarrhythmic drugs.

Authors: J Caron; C Libersa
Journal: Drug Saf Date: 1997-07 Impact factor: 5.606

3. Efficacy of THN102 (a combination of modafinil and flecainide) on vigilance and cognition during 40-hour total sleep deprivation in healthy subjects: Glial connexins as a therapeutic target.

Authors: Fabien Sauvet; Mégane Erblang; Danielle Gomez-Merino; Arnaud Rabat; Mathias Guillard; Dominique Dubourdieu; Hervé Lefloch; Catherine Drogou; Pascal Van Beers; Clément Bougard; Cyprien Bourrrilhon; Pierrick Arnal; Werner Rein; Franck Mouthon; Francoise Brunner-Ferber; Damien Leger; Yves Dauvilliers; Mounir Chennaoui; Mathieu Charvériat
Journal: Br J Clin Pharmacol Date: 2019-09-15 Impact factor: 4.335

Is there a genetic factor in flecainide toxicity?

1. Polymorphic drug oxidation in humans.

2. Oral flecainide acetate for the treatment of ventricular arrhythmias.

3. Pharmacodynamics and side effects of flecainide acetate.

1. Acquired long QT syndrome and ventricular tachycardia in a patient on flecainide therapy.

Review 2. Adverse effects of class I antiarrhythmic drugs.

3. Efficacy of THN102 (a combination of modafinil and flecainide) on vigilance and cognition during 40-hour total sleep deprivation in healthy subjects: Glial connexins as a therapeutic target.

Review 4. Physiological changes due to age. Pharmacodynamic changes of drug action and implications for therapy.

5. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

6. Is there a genetic factor in flecainide toxicity?

7. Altered flecainide disposition in healthy volunteers taking quinine.

8. Estimation of the absolute bioavailability of flecainide using stable isotope technique.

Review 9. Clinical significance of genetic influences on cardiovascular drug metabolism.

10. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype.